Search

A method by high-performance liquid chromatography (HPLC) with UV-detection was developed for the determination of the active substances hymexazol, tefluthrin, sedaxane, fludioxonil, metalaxyl-M, thiamethoxam, imidacloprid, clothianidin and β-cyfluthrin in pelleted sugar beet seed. The method performance was investigated in a round-robin study in 2021. In this study, ten laboratories analyzed 15 different seed samples, provided by five manufacturers. For each sample, two representative portions of 100 pelleted seeds were analyzed. In general, the highest recovery rates were obtained using an extraction solvent consisting of 95% acetone, 4% water and 1% phosphoric acid and this solvent was therefore selected as the preferred solvent for the simultaneous extraction of the different active substances from the pelleted seeds. However, slightly higher recovery rates for hymexazol were obtained using a mixture of 80% acetone, 19% water and 1% phosphoric acid. This solvent remains an alternative for the analysis of hymexazol. The presented and validated method may serve as an internationally recognized reference method for the analysis of different fungicides and insecticides in pelleted sugar beet seeds from different origin.

Pyrethroid-chlorfenapyr nets have demonstrated improved entomological and epidemiological impact in trials across Africa. This is driving increased demand for this novel net class in malaria endemic countries. PermaNet® Dual is a new deltamethrin-chlorfenapyr net developed by Vestergaard Sàrl to provide more options to malaria control programmes. We performed an experimental hut trial to evaluate the efficacy of PermaNet® Dual against wild, free-flying pyrethroid-resistantAnopheles gambiae sensu latoin Covè, Benin. PermaNet® Dual induced superior levels of mosquito mortality compared to a pyrethroid-only net and a pyrethroid-piperonyl butoxide net both when unwashed (77% with PermaNet® Dual vs. 23% with PermaNet® 2.0 and 56% with PermaNet® 3.0, p

Purpose: The available questionnaires for quality-of-life (QoL) assessments are age-group specific, limiting comparability and impeding longitudinal analyses. The comparability of measurements, however, is a necessary condition for gaining scientific evidence. To overcome this problem, we assessed the viability of harmonising data from paediatric and adult patient-reported outcome (PRO) measures. Method: To this end, we linked physical functioning scores from the Paediatric Quality of Life Inventory (PedsQL) and the Paediatric Quality of Life Questionnaire (PEDQOL) to the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30) for adults. Samples from the EURAMOS-1 QoL sub-study of 75 (PedsQL) and 112 (PEDQOL) adolescent osteosarcoma patients were concurrently administered both paediatric and adult questionnaires on 98 (PedsQL) and 156 (PEDQOL) occasions. We identified corresponding scores using the single-group equipercentile linking method. Results: Linked physical functioning scores showed sufficient concordance to the EORTC QLQ-C30: Lin's r Z 0.74 (PedsQL) and Lin's r Z 0.64 (PEDQOL). Conclusion: Score linking provides clinicians and researchers with a common metric for assessing QoL with PRO measures across the entire lifespan of patients. (C) 2022 The Author(s). Published by Elsevier Ltd.

Background The quality of life (QoL) of patients with osteosarcoma (OS) may be adversely affected by the disease or its treatment. Therefore, it is important to understand the QoL of patients undergoing treatment for OS to improve the QoL. We report on the first prospective international QoL study that was embedded within a large randomized clinical trial from 4 national study groups. Objective This paper aimed to describe the QoL study development, methodology, accrual details, and characteristics of the QoL cohort. Methods A total of 2260 patients registered in the EURopean AMerican Osteosarcoma Study-1 (EURAMOS-1), of whom 97.92% (2213/2260) were eligible for the optional QoL assessment and could participate in terms of questionnaire availability. Overall, 61.86% (1369/2213) of patients and/or proxies completed the QoL evaluation at the first assessment time point (E1) after the start of preoperative treatment. The QoL measures used (self- and/or proxy reports) depending on the patient’s age and national study group. Participants and nonparticipants in the ancillary QoL study were compared regarding relevant demographic and disease-related characteristics at registration in the trial. Results The participation rate at time point E1 did not differ with regard to age, gender, the occurrence of pathological fracture, or the presence of any metastases at diagnosis. No differences were found regarding the primary tumor site. Only the national study group affiliation had an influence on participation. Participation decreased linearly with trial progress up to 20% at the final time point of QoL assessment. Conclusions This study demonstrates the feasibility of international cooperation for the purpose of assessing and understanding the QoL of pediatric and adolescent/young adult patients with cancer. Future outcomes of this QoL substudy will help to adapt interventions to improve QoL.